SRRK Projected Dividend Yield
Scholar Rock Holding Corp ( NASDAQ : SRRK )Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling. 20 YEAR PERFORMANCE RESULTS |
SRRK Dividend History Detail SRRK Dividend News SRRK Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |